Zoladex 10.8 mg – Composition, Uses and Medicine Enquiries
Product Overview
Zoladex 10.8 mg is a product listed under the hormonal anticancer therapy category and is classified as a gonadotropin-releasing hormone (GnRH) agonist.
Its active composition is Goserelin acetate 10.8 mg depot.
It is associated with selected hormone-sensitive prostate cancer and other label-approved conditions.
The active ingredient initially stimulates and then suppresses gonadotropin signalling, lowering sex-hormone production.
Suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
This information is provided for education and product identification, not as a recommendation to begin treatment.
Zoladex 10.8 mg is a depot implant, not an oral tablet. Market-specific indications and administration schedules must be confirmed against the approved product information.
A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Goserelin acetate | 10.8 mg depot |
Product Name: Zoladex 10.8 mg
Generic Name: Goserelin acetate
Brand Name: Zoladex
Strength: 10.8 mg
Please verify the exact strength, depot formulation, dosage form and manufacturer details against the original product packaging before publishing this product page or proceeding with an enquiry.
Therapeutic Category and Indication
Zoladex 10.8 mg belongs to the hormonal anticancer therapy category and is classified as a GnRH agonist.
Its clinical use relates to selected hormone-sensitive prostate cancer and other label-approved conditions.
The active ingredient initially stimulates and then suppresses gonadotropin signalling, lowering sex-hormone production.
Treatment eligibility may depend on diagnostic tests, patient-specific factors, coexisting conditions, other medicines and the relevant national prescribing information.
The exact approved uses and restrictions should be checked against the current local prescribing information.
The market-specific indications and administration schedule must be confirmed before publication.
Administration Information
Zoladex 10.8 mg is administered as a depot implant by a trained healthcare professional.
A trained clinician administers the depot implant under the skin at the approved interval.
Patients should follow the exact prescribed route, dose and schedule.
Do not change, share or discontinue this medicine without the treating professional’s advice.
The prescribed schedule, duration, missed-dose instructions and monitoring requirements must be provided by the treating clinician.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: Zoladex 10.8 mg.
- Generic Name: Goserelin acetate.
- Brand Name: Zoladex.
- Strength: 10.8 mg.
- Therapeutic Category: Anticancer.
- Medicine Class: GnRH Agonist.
- Indication: Selected hormone-sensitive prostate cancer and other label-approved conditions.
- Dosage Form: Depot Implant.
- Route of Administration: Subcutaneous.
The master spreadsheet lists AstraZeneca as manufacturer/marketer. This attribution and the current pack size, dosage form, labeling, batch details and expiry must be independently verified.
Available packaging, batch identification, expiry date and remaining shelf life can vary and should be confirmed by an authorised supplier before any transaction.
A product listing does not confirm current stock, price, availability or eligibility for supply to a particular destination.
Prescription and Patient Safety
Zoladex 10.8 mg is a prescription hormonal anticancer medicine and requires appropriate specialist supervision.
Treatment suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
This is a depot implant, not an oral tablet. The exact administration schedule and market-specific indications should be checked against the approved product information.
Patients should follow their treating clinician’s instructions and should not independently change or discontinue treatment.
The exact precautions, monitoring requirements and possible adverse effects should be checked against the current approved product information.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal provides medicine information, product identification and enquiry coordination. Where appropriate, Medinglobal may help patients, caregivers and eligible healthcare organisations communicate with independent, appropriately authorised pharmaceutical suppliers or service providers.
Medinglobal does not manufacture, stock, sell, dispense or prescribe Zoladex 10.8 mg through the website.
Any regulated pharmaceutical activity, including prescription verification and lawful supply, remains the responsibility of the relevant independent provider and is subject to applicable laws and regulations.
Availability, prescription requirements, lawful supply routes, supporting documents and destination-country restrictions must be confirmed before any transaction.
Submitting an enquiry does not guarantee supply or availability.
How to Submit a Zoladex 10.8 mg Enquiry
To help identify the requested product, include the following details when submitting an enquiry:
- Product or brand name: Zoladex 10.8 mg.
- Generic name: Goserelin acetate.
- Required strength and depot formulation.
- Required quantity.
- Destination country.
- Prescription or supporting documentation, where applicable.
Medinglobal may review the submitted details for identification and coordination purposes and, where appropriate, refer the enquiry to an authorised independent provider.
The provider is responsible for its own verification, regulatory checks and any subsequent supply decision.
Frequently Asked Questions
What is Zoladex 10.8 mg used for?
Zoladex 10.8 mg is associated with selected hormone-sensitive prostate cancer and other label-approved conditions, subject to the exact approved product information and medical assessment.
What does Zoladex 10.8 mg contain?
It contains Goserelin acetate 10.8 mg depot. The exact composition should be confirmed against the original manufacturer-labelled packaging.
What type of medicine is Zoladex 10.8 mg?
It belongs to the hormonal anticancer therapy category and is classified as a GnRH agonist.
How is Zoladex 10.8 mg administered?
A trained clinician administers the depot implant under the skin at the approved interval.
Is Zoladex 10.8 mg an oral tablet?
No. It is a depot implant, not an oral tablet.
Can international patients submit a Zoladex enquiry through Medinglobal?
International enquiries may be submitted. Any coordination or subsequent supply depends on confirmation by an authorised independent provider and compliance with applicable regulations.
Does Medinglobal sell or dispense Zoladex directly?
No. Medinglobal provides product information, identification and enquiry coordination. It does not itself manufacture, sell, dispense or prescribe the medicine through the website.




Reviews
There are no reviews yet.